Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%

Arcus Biosciences, Inc.

Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.
Gilead's exclusive option for casdatifan expired without exercise; Arcus retains full global rights.
ARC-20 in ccRCC: 50mg BID median PFS 9.7 months, ORR 25%; 100mg QD ORR 33%.
Disease control rate 81-87% across cohorts; median DoR not reached; safety acceptable.
All but two of 26 responders remained on treatment; one discontinuation due to anemia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.